Knowledge and Current Practices in Monogenic Uveitis: An International Survey by IUSG and AIDA Network
Introduction This study aims to explore awareness, knowledge, and diagnostic/therapeutic practices in monogenic uveitis (mU) among uveitis experts. Methods This is an explorative, cross-sectional survey study. An anonymous, semi-structured, electronic survey was delivered to uveitis experts from the Autoinflammatory Diseases Alliance (AIDA) Network and International Uveitis Study Group (IUSG). We included respondents answering ≥ 50% of the survey. Results Seventy-seven participants rated their knowledge of mU as proficient (3.9%), adequate (15.6%), sufficient (16.9%), or poor (63.6%). When asked about the first mU gene they thought of, 60.4% mentioned NOD2, 3.9% mentioned NLRP3 or MEFV, and 49.4% provided incorrect or no answers. Success rates in clinical scenarios varied from 15.6% to 55.8% and were higher for ophthalmologists working in multidisciplinary teams (p < 0.01). Genetic testing was ordered for suspected mU by 41.6% of physicians. The availability of molecular techniques did not significantly differ based on geography (p > 0.05). The public healthcare system ensured a higher percentage of tests prescribed were obtained by patients compared to private insurances (p < 0.00). In terms of disease-modifying anti-rheumatic drugs (DMARDs), tumor necrosis factor-α inhibitors were the most familiar to uveitis experts. The difficulties with off-label therapy procedures were the primary barrier to DMARDs prescription for patients with mU and correlated inversely with the obtained/prescribed drug ratio for interleukin-1 (p < 0.01) and interleukin-6 (p < 0.01) inhibitors. Conclusions This survey identifies proficiency areas, gaps, and opportunities for targeted improvements in patients care. The comprehensive outputs may inform evidence-based guidelines, empowering clinicians with standardized approaches, and drive an AIDA Network—IUSG unified effort to advance scientific knowledge and clinical practice..
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
---|---|
Enthalten in: |
Ophthalmology and therapy - 13(2023), 1 vom: 04. Nov., Seite 127-147 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Gaggiano, Carla [VerfasserIn] |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
Autoinflammatory diseases |
---|
Anmerkungen: |
© The Author(s) 2023 |
---|
doi: |
10.1007/s40123-023-00839-1 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
SPR05432842X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | SPR05432842X | ||
003 | DE-627 | ||
005 | 20240110064651.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240110s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1007/s40123-023-00839-1 |2 doi | |
035 | |a (DE-627)SPR05432842X | ||
035 | |a (SPR)s40123-023-00839-1-e | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Gaggiano, Carla |e verfasserin |4 aut | |
245 | 1 | 0 | |a Knowledge and Current Practices in Monogenic Uveitis: An International Survey by IUSG and AIDA Network |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a © The Author(s) 2023 | ||
520 | |a Introduction This study aims to explore awareness, knowledge, and diagnostic/therapeutic practices in monogenic uveitis (mU) among uveitis experts. Methods This is an explorative, cross-sectional survey study. An anonymous, semi-structured, electronic survey was delivered to uveitis experts from the Autoinflammatory Diseases Alliance (AIDA) Network and International Uveitis Study Group (IUSG). We included respondents answering ≥ 50% of the survey. Results Seventy-seven participants rated their knowledge of mU as proficient (3.9%), adequate (15.6%), sufficient (16.9%), or poor (63.6%). When asked about the first mU gene they thought of, 60.4% mentioned NOD2, 3.9% mentioned NLRP3 or MEFV, and 49.4% provided incorrect or no answers. Success rates in clinical scenarios varied from 15.6% to 55.8% and were higher for ophthalmologists working in multidisciplinary teams (p < 0.01). Genetic testing was ordered for suspected mU by 41.6% of physicians. The availability of molecular techniques did not significantly differ based on geography (p > 0.05). The public healthcare system ensured a higher percentage of tests prescribed were obtained by patients compared to private insurances (p < 0.00). In terms of disease-modifying anti-rheumatic drugs (DMARDs), tumor necrosis factor-α inhibitors were the most familiar to uveitis experts. The difficulties with off-label therapy procedures were the primary barrier to DMARDs prescription for patients with mU and correlated inversely with the obtained/prescribed drug ratio for interleukin-1 (p < 0.01) and interleukin-6 (p < 0.01) inhibitors. Conclusions This survey identifies proficiency areas, gaps, and opportunities for targeted improvements in patients care. The comprehensive outputs may inform evidence-based guidelines, empowering clinicians with standardized approaches, and drive an AIDA Network—IUSG unified effort to advance scientific knowledge and clinical practice. | ||
650 | 4 | |a Autoinflammatory diseases |7 (dpeaa)DE-He213 | |
650 | 4 | |a Differential diagnosis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Genetic uveitis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Pathogenesis |7 (dpeaa)DE-He213 | |
650 | 4 | |a Rare diseases |7 (dpeaa)DE-He213 | |
700 | 1 | |a Gupta, Vishali |4 aut | |
700 | 1 | |a Agrawal, Rupesh |4 aut | |
700 | 1 | |a De Smet, Marc D. |4 aut | |
700 | 1 | |a Frediani, Bruno |4 aut | |
700 | 1 | |a Tosi, Gian Marco |4 aut | |
700 | 1 | |a Paroli, Maria Pia |4 aut | |
700 | 1 | |a Sridharan, Sudharshan |4 aut | |
700 | 1 | |a Pavesio, Carlos E. |4 aut | |
700 | 1 | |a Pleyer, Uwe |4 aut | |
700 | 1 | |a Denisova, Ekaterina V. |4 aut | |
700 | 1 | |a Babu, Kalpana |4 aut | |
700 | 1 | |a de-la-Torre, Alejandra |4 aut | |
700 | 1 | |a Yang, Peizeng |4 aut | |
700 | 1 | |a Davis, Janet L. |4 aut | |
700 | 1 | |a Cunningham, Emmett T. |4 aut | |
700 | 1 | |a Carreño, Ester |4 aut | |
700 | 1 | |a Goldstein, Debra |4 aut | |
700 | 1 | |a Fonollosa, Alex |4 aut | |
700 | 1 | |a Cantarini, Luca |0 (orcid)0000-0002-7352-1275 |4 aut | |
700 | 1 | |a Sobrin, Lucia |4 aut | |
700 | 1 | |a Fabiani, Claudia |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Ophthalmology and therapy |d Berlin : SpringerOpen, 2012 |g 13(2023), 1 vom: 04. Nov., Seite 127-147 |w (DE-627)SPR032898037 |w (DE-600)2682230-1 |x 2193-6528 |7 nnns |
773 | 1 | 8 | |g volume:13 |g year:2023 |g number:1 |g day:04 |g month:11 |g pages:127-147 |
856 | 4 | 0 | |u https://dx.doi.org/10.1007/s40123-023-00839-1 |z kostenfrei |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_SPRINGER | ||
951 | |a AR | ||
952 | |d 13 |j 2023 |e 1 |b 04 |c 11 |h 127-147 |